Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Gloria Salvo(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Abdulrazzak Zarifa(The University of Texas MD Anderson Cancer Center), Abdulrahman Abonofal(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Mingxuan Xu(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|1990|1.4k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508